Anlotinib in combination with Envolizumab plus Etoposide for the treatment of EX-SCLC:a case report  

作　　者：Hong-Lei Guo Hong Wang Yan-Qi Song Xin-Long Song Ai-Di Wang Bao-Shan Liu 

机构地区：[1]Graduate School,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China [2]Department of Chinese Medicine,Tianjin Medical University General Hospital,Tianjin 300052,China

出　　处：《Clinical Research Communications》2024年第1期29-33,共5页临床研究通讯

摘　　要：Background:Small cell lung cancer(SCLC)is an aggressive malignant tumor with strong immunosuppressive effects,characterized by rapid doubling time and poor prognosis.Currently,effective therapeutic options are urgently needed for Extensive-stage small-cell lung Cancer.Case description:In the present case,a combination therapy of anlotinib,envolizumab,and etoposide was administered to treat an 80-year-old female patient with extensive-stage SCLC accompanied by mediastinal lymph node and bone metastasis.After two cycles of treatment,the tumor lesions in the right lungs decreased from 5.04*3.44 cm to 1.65*1.42 cm.As of now,no significant mass is seen there and no serious adverse reactions in this patient.Until September 2023,she has survived for 18 months with no disease progression.Conclusions:Research shows that Alectinib,in combination with evolocumab plus etoposide,could be an original,viable therapeutic option for the treatment option of patients with extensive-stage SCLC.

关 键 词：Extensive-stage Small Cell Lung Cancer ANTI-ANGIOGENESIS PD-1 inhibitors Combined treatment case report 

分 类 号：R73[医药卫生—肿瘤]